European Syringe Collection and Analysis Enterprise: generic protocol. by unknown
February 2021 








Introduction __________________________________________________________ 3 
Objectives ___________________________________________________________ 3 
Primary objective __________________________________________________________ 3 
Secondary objectives ______________________________________________________ 3 
Ethical considerations _________________________________________________ 4 
Methods _____________________________________________________________ 4 
Study methods ____________________________________________________________ 4 
Study design _____________________________________________________________________ 4 
Study population __________________________________________________________________ 4 
Study period _____________________________________________________________________ 4 
Outcomes _______________________________________________________________________ 4 
Sampling ________________________________________________________________ 4 
Sample size ______________________________________________________________________ 4 
Sampling sites ____________________________________________________________________ 4 
Sampled material _________________________________________________________________ 5 
Macroscopic and microscopic observations ___________________________________ 7 
Laboratory analysis ________________________________________________________ 7 
Sample preparation ________________________________________________________________ 7 
Analytical methods ________________________________________________________________ 9 
Data management and analysis _________________________________________ 9 
Data collection ____________________________________________________________ 9 
Codebook _______________________________________________________________________ 9 
Data flow _______________________________________________________________________ 10 
Data analysis ____________________________________________________________ 11 
Primary indicators ________________________________________________________________ 11 
Other indicators __________________________________________________________________ 11 
References _________________________________________________________ 11 
Annexes ____________________________________________________________ 12 
Annex 1 Definitions _______________________________________________________ 12 
Annex 2 Safety equipment and supplies ______________________________________ 13 
Annex 3 List of drugs, adulterants and metabolites tested for, by city _____________ 14 
Annex 4 Analytical methods used by laboratories (first two campaigns) ___________ 17 




Monitoring of illicit drug use may be difficult, particularly among people who inject drugs, because of the 
associated stigma. Some people who inject drugs access harm reduction programmes such as needle 
exchange programmes, where they can return used injecting material and get new and sterile material. It 
is a cost-effective intervention that reduces the risk of drug-related infectious diseases. Depending on the 
country and cities where people who inject drugs live, different types of services may be available to 
them, including low-threshold facilities, drug treatment services, pharmacies and drug consumption 
rooms. Information on injecting drug use practices can be obtained from surveys conducted in these 
structures, often on a self-report basis. However, surveys are not always feasible, and people who inject 
drugs that do not access these services are not reached. In addition, in the case of new substances 
emerging locally, drug users might not be aware of the real composition of the drugs.  
This protocol documents a new approach that has been developed to monitor substances injected by 
people who inject drugs through analytically confirmed data at the local level: the analysis of residual 
content of used syringes (Néfau et al., 2015). Used syringes contain traces of drugs that can be analysed 
to inform public health professionals about injecting drug use, and to contribute to the understanding of 
drug addiction among people who inject drugs. Used syringes can be collected from low-threshold 
services where needle exchange programmes are in place. They can also be collected from automatic 
injection kit dispensers (AIKD) combined with street bins (where people who inject drugs can obtain their 
new sterile injection kit in return of a used syringe), thereby obtaining injecting material from populations 
that might not be in contact with health and social services.  
This method was first implemented by research teams and low-threshold services in France (Paris) 
(Néfau et al., 2015), Hungary (Budapest) (Péterfi et al., 2018) and Switzerland (Lausanne) (Lefrançois et 
al., 2016). In 2017, the EMCDDA supported its French focal point (Observatoire Français des Drogues et 
des Toxicomanies) in developing a partnership with European peers involved in this research in order to 
set up a European multi-city study – the European Syringe Collection and Analysis Enterprise (ESCAPE). 
The aim of this project is to coordinate a yearly collection campaign of used syringes in a sentinel network 
of European cities, using a common methodology in order to obtain representative and comparable data 
on injecting drug use. This generic protocol outlines the methodology. It is used by participating study 
sites to develop their own study protocol, taking into account local specificities while guaranteeing a 
common European analysis.  
Objectives 
Primary objective 
The primary objective is to provide public health professionals with laboratory-confirmed information on 
substances injected by people who inject drugs in a sentinel network of European cities, including 
marginalised people who inject drugs who are not using social and health services, and detect new trends 
by: 
• assessing the frequency and percentage of occurrences of drug detection in syringes, by city, by 
year; 
• assessing the frequency and percentage of occurrences of different drug combinations, by city, 
by year. 
Secondary objectives 
In addition, the project will seek to: 
• assess the frequency and percentage of occurrences of adulterant detection, by drug, by city, by 
year; 
• assess the extent of syringe reuse. 




No data on individuals are collected in the ESCAPE project. The unit of analysis is the syringe. The 
results for each syringe can be traced back to a collection site, but not to any individual user. 
Each study team is responsible for getting ethical approval if required at the national level. 




ESCAPE is a multi-city observational study, with multiple data collection sites in each participating city. 
Yearly, collection and analyses of a sample of used syringes is conducted in each participating city. 
Study population 
While the unit of analysis is the syringe, the study population is people who inject drugs who use services 
or street bins provided at the sites where samples are collected. 
This population may include people who are not in contact with drug services, if samples are collected 
from street bins of automatic injection kit dispensers. 
The study population may differ by demographic and socio-economic characteristics across collection 
sites and cities.  
Study period 
One collection campaign is conducted every year. The collection campaign lasts for one month. The 
month of syringe collection is agreed by the network at the beginning of each year. 
Outcomes 
Identification of substances which are contained in used syringes (see List of substances in Annex). 
Identification of combinations of substances which are contained in used syringes. 
If possible: macroscopic and microscopic observations (blood traces, damaged needles, etc.). 
Sampling 
Sample size 
In order to maximise representativeness, a minimum of 150 syringes should be collected in each 
participating city. 
Sampling sites 
Location of sampling sites 
If possible, five sites should be selected within each participating city. Sites should be located in distinct 
neighbourhoods, preferably with various demographic and socio-economic characteristics. The 
geographical distribution of sites should offer a good coverage of the city. 
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Depending on the number of sites per city, the syringe collection campaigns should follow the following 
minimum sample size distribution: 
• 1 site: a minimum of 150 syringes, 
• 2 sites: a minimum of 75 syringes per site, 
• 3 sites: a minimum of 50 syringes per site, 
• 4 sites: a minimum of 38 syringes per site, 
• 5 sites: a minimum of 30 syringes per site. 
Types of sampling sites 
The choice of the type of sites where syringes are collected depends on their availability in the 
participating city. Research teams should provide a description of the sites where collection takes place 
(type of structure, description of the area) as well as contextual information (city population size, people 
who inject drugs population size estimate for the city, number of clean syringes distributed per year in the 
city, etc.). There are three main types of sites where data collection can take place.  
• Bins of street automatic injection kit dispensers (AIKD): people who avail of AIKD are not 
well known by field workers. Syringes collected from AIKD can therefore provide drug use 
information on a population that might not be in contact with social and health services. 
• Low-threshold facilities or drop-in structures with needle and syringe programmes: 
collection may be conducted in low-threshold services where needle exchange programmes 
are implemented. In this case, people who exchange their used syringes are usually in 
contact with social and/or health workers. While not within the scope of this protocol, a small-
scale survey can be conducted during syringe collection in order to obtain complementary 
information on injection practices (reuse, sharing).   
• Drug consumption rooms (DCR): similarly, syringe collection may be conducted in DCR, 
where people can inject drugs under the supervision of medically trained staff. Syringe 
collection should not interfere with the operation of the DCR. Information on the drugs injected 
can be useful to the DCR staff, allowing them to confirm the main drugs injected and to detect 
emerging ones and thereby tailor harm reduction strategies accordingly.  
Sampled material 
Inclusion criteria 
Used syringes from specific street bins or from dedicated facilities (see section on the types of sampling 
sites) are included provided that have been disposed of not more than one month before the collection 
campaign. 
In bins of street automatic injection kit dispensers:  
• only 1 cc syringes should be collected (usually AIKD bins are designed to collect 1 cc syringes 
only). 
In dedicated facilities, the volume of syringes can vary: 
• collecting 1 cc syringes is preferable;  
• syringes of other sizes can be collected depending on the injecting practices in the city. 
The volume of each analysed syringe should be recorded on the data collection tool. 
Exclusion criteria 
Excluded are syringes: 
• that have been disposed of more than one month before the collection campaign or for which it is 
not possible to determine the maximum time since disposal; 
• with a broken barrel; 
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• that cannot be pumped (as this can happen when they are clogged with blood, it is important to 
collect more syringes than the minimum requested). 
Randomisation and selection 
Manipulating syringes is hazardous because of the risk of accidental blood exposure and potential 
exposure to blood-borne viruses. It is crucial to respect safety measures and to use specific equipment 
(see Annex 2) to reduce the risks.  
• All syringes must be collected in a sharps container. The sharps container should be large 
enough to be shaken in order to mix all syringes collected. Mixing the syringes will reduce the 
chances of including too many syringes from the same user.  
• The sharps box should then be opened and the syringes tipped from it onto a flat surface – taking 
care not to stack them on top of one another – before being removed for analysis using a 
laboratory tongs or by hand wearing protective gloves (see Figure 1). 
• If it is not possible to shake the box before laying the syringes on a flat surface, syringes should 
be selected randomly on the flat surface. 
• If syringes are collected in low-threshold services or DCRs, boxes brought by the different users 
are emptied in a larger box which is then shaken in order to mix all collected syringes. Then, the 
same procedures described in Figure 1 should be applied to select the syringes. 
 
FIGURE 1 
Safety measures to collect and select syringes 
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Macroscopic and microscopic observations 
Different characteristics of the collected syringes can be observed. These characteristics can be useful 
when interpreting the results and should be recorded. 
Blood traces. The detection of a drug in a syringe indicates that the syringe was used to inject the drug. 
In some cases, an alternative explanation is that the drug (or its metabolite) may come from traces of 
blood drawn into the syringe during an injection. In such a case, the user would have consumed the drug 
prior to the injection, possibly through other modes of administration (e.g. smoking, snorting). Recording 
the presence of visible blood traces in syringes could help assess the extent of this measurement bias.   
Attrition marks. The presence of wear marks (e.g. erased graduations) on the syringe can indicate 
several manipulations and consequently can be an indicator of reuse. 
Distinctive signs. If the same signs (e.g. coloured syringe plunger) are observed on several syringes, it 
can indicate that these syringes have been brought by the same user and help assess the extent of 
selection bias.  
Damaged needle (microscopic observation). Needles presenting attrition might have been used more 




Syringes should be rinsed up to five times with methanol (MeOH). The maximum volume of MeOH 
generally used is 1 ml. An alternative to filtration is centrifugation of the samples (2000 rev/min for 
5 minutes). 
To reduce blood exposure risks, the sample preparation method illustrated in Figure 2 is recommended.  
In the event of needle injury with possible blood exposure, put your hand (or the injured part of your body) 
into a basin with bleach and press the wound to evacuate blood. After 2 minutes, put a swab on the 
wound and go to hospital to report the incident, where doctors can prescribe post-exposure prophylaxis 
against HIV. 
 














Different analytical methods can be used (gas chromatography (GC), ultra-high- or high-performance 
liquid chromatography (UHPLC or HPLC) coupled with mono or tandem mass spectrometry (MS or 
MS/MS) but it is recommended to use a screening method. Screening methods allow a wider range of 
substances to be detected (including new substances). If a target method is used, a required minimum list 
of substances has been established, including classical drugs, new psychoactive substances (NPS) and 
medicines which are known to be injected in participating cities (Annex 3). Several cutting agents, 
degradation products and metabolites are also included in that list. The minimum set of substances is 
reviewed each year by the network. 
The required minimum list of substances is complemented by any other substances that the participating 
research teams wish to investigate, depending on local specificities or on the analytical methods used 
(Annex 3).  
Methods used by some of the ESCAPE study teams are documented in Annex 4 and have also been 
described in the literature (Gjerde et al., 2020; Lefrançois et al., 2016; Néfau et al., 2015; Péterfi et al., 
2018). They can be reproduced and used by other laboratories. Depending on the analytical equipment 
available, it is possible to develop and use other methods. The aim is to be able to detect at least the 
substances from the required minimum set of substances, and as many other substances as possible 
(Annex 3). 
No blood analyses (e.g. rhesus or DNA analyses) will be conducted. 
Data management and analysis 
Data collection 
Codebook 
Participating sites report data on each syringe analysed using a standardised spreadsheet with the 
variables listed in the codebook (Table 1). The list of variables is reviewed each year and the trade-off 
between information and workload of study teams is assessed. 
TABLE 1 
ESCAPE codebook 
Variable name Description Value 
IDUNIQUE IDUNIQUE is a unique identifier for each 
syringe within a particular study year 
=CONCATENATE(COL3;“_”;
COL5; “_”;COL4) 
COUNTABR 2-Letter or 3-letter country codes for 
participating countries 
FIN, FRA, DEU, HUN,… 
ID        Code given to each syringe by the 
laboratory 
S1, S2, S3… 
DATECOL Date when the syringe was collected DD/MM/YYYY 
LOC Name or code of the location where the 
syringe was conducted. Several sites (5 
max) for each city   
L1, L2, L… 
CITY City code of participating cities AMS, BUD, COL, GLA, HEL, 
LAU, PAR… 
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Variable name Description Value 
STRTYPE Type of structure where the collection is 
performed: automatic injection kit 
dispensers/low-threshold 
facilities/supervised injecting centre (or 
injecting room) 
AIKD, LT, SSIR  
X_WGS84 World Geodetic System 1984 variable X 
(longitude) 
 
Y_WGS85 World Geodetic System 1984 variable Y 
(latitude) 
 
Unmade extraction Unmade extraction Yes/No 
Blood Presence of blood traces Yes/No 
Broken needle Broken needle Yes/No 
Attritions  Attrition marks Yes/No 
Signs Distinctive signs Yes/No 
Difficult to rinse Problems rinsing the syringe Yes/No 
DATEANAL Date of syringe analysis DD/MM/YYYY 
Substance List of substances detected See Annex 3 
Data flow 
The standardised spreadsheets are then validated and included in a centralised European database at 
the EMCDDA where further data management and data analysis are performed (Figure 3).  
FIGURE 3 
ESCAPE data flow 
 





The main geographical unit of analysis is the city. 
• Counts of syringes analysed, by city, by year 
• Counts and proportion of syringes testing positive for at least one drug category, by city, by year 
• Counts and proportion of syringes testing positive, by drug category, by city, by year 
o The denominator for the proportion is all syringes testing positive for at least one drug 
category 
• Counts and proportion of syringes testing positive for more than one drug category, by 
combination of drug categories, by city, by year 
o The denominator for the proportion is all syringes testing positive for at least one drug 
category 
Other indicators 
• Counts and proportion of syringes testing positive for at least one drug, by city, by year 
• Counts and proportion of syringes testing positive, by drug, by city, by year 
o The denominator for the proportion is all syringes testing positive for at least one drug 
category 
• Counts and proportion of syringes testing positive for more than one drug, by combination of 
drug, by city, by year 
o The denominator for the proportion is all syringes testing positive for at least one drug 
category 
• Counts and proportion of syringes testing positive for adulterants, by drug, by city, by year 
o The denominator for the proportion is syringes testing positive for the drug of interest 
Other geographical units of interest might include sites (within cities) and overall results (pooling of 
European results).  
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Annex 1 Definitions 
• Adulterant: A pharmacologically active compound that dealers mix with drugs to increase the 
volume of the product in order to maximise profits. For instance, levamisole – originally an 
anthelmintic medication, which has some antidepressant properties – is a common adulterant of 
cocaine. Pharmacologically inert diluents (such as sugar) were not screened for in this study. 
• By-product of production: Some drugs may be the result of the production process of another 
drug. For instance, codeine traces might be found in heroin. 
• Degradation product: A compound resulting from the natural breakdown of a drug over time. 
The degradation of a drug can occur in the syringe. For instance, heroin will naturally degrade 
into 6-MAM (6-monoacetylmorphine) and morphine. In the analysis, any syringe testing positive 
for 6-MAM in the presence of morphine, codeine or meconin was assumed to have once 
contained heroin and was reclassified as a ‘heroin syringe’.  
• Drug: A psychoactive substance consumed with the aim of altering the user’s mood and 
perception, through its effect on the central nervous system. 
• Drug category: In order to simplify the presentation of results for the large number of substances 
covered in this study, drugs were grouped into 17 drug categories according to their public health 
relevance and on the basis of their shared characteristics. The categories may thus combine 
chemical, pharmacological and use perspectives. For example, heroin and methadone are 
reported separately from ‘other opioids’ and ‘other medications’, respectively. Some drug 
categories (e.g., cocaine) include a single drug, while others (e.g., synthetic cathinones) include 
several drugs 
• Metabolite: Metabolites are residues of a drug after it is broken down in the body. They can be 
found in the blood, urine or faeces of users after consumption of the drug regardless of the route 
of administration. Blood containing metabolites can enter a syringe during injection. In this study, 
tests were carried out for metabolites of heroin (6-MAM), cocaine (benzoylecgonine) and 
benzodiazepines (7-aminoclonazepam). Some metabolites, for instance 6-MAM, can also result 
from degradation. Syringes testing positive only for metabolites were excluded from the analysis. 
• Syringe will refer to a needle and/or a barrel, depending on the ability of the partners on the field 
to collect each of those parts. In some cities, people who inject drugs visit their needle and 
syringe programme to get new needles (or a ‘puck’ of 42 sterile needles) as they give back their 
used ones. In these cities, field workers are therefore much more likely to gather needles than 
barrels. 
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Annex 2 Safety equipment and supplies 
Manipulating syringes is hazardous because of the risk of accidental blood exposure and potential 
exposure to blood-borne viruses. It is crucial to respect safety measures and to use specific equipment to 
reduce the risks. In the context of the COVID-19 pandemic, we added protective masks to the list of 
safety equipment. Disinfection of protective equipment should be done thoroughly. Each study team must 
conduct its collection campaign and analysis in accordance with their national health and safety 
recommendations. 
Minimum set of required safety equipment 
Laboratory coat Safety glasses Concentrated bleach 
solution 
Needle resistant gloves Laboratory tongs Protective mask 
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Amphetamines Amphetamine x x x x x x x x 
Methamphetamine x x x x x x x x 
Cocaine Cocaine x x x x x x x x 
Heroin Heroin x x x x x x x x 
Morphine Morphine x x x x x x x x 
Buprenorphine Buprenorphine x x x x x x x x 
Naloxone Naloxone x x x x x x x x 
Methadone Methadone x x x x x x x x 
Fentanyl and 
derivatives 
3-methylfentanyl x x x x x   x 
4-Chloro-isobutyrfentanyl x x x x x x  x 
4-Fluoro-isobutyryl fentanyl x x x x x x  x 
4-Methoxy-butyryl fentanyl x x x x x x  x 
Acetylfentanyl x x x x x x x x 
Acrylfentanyl x x x x x x  x 
Alfentanil x x x x x x  x 
Butyrylfentanyl x x x x x x  x 
Carfentanil x x x x x x x x 
Cyclopentylfentanyl x x x x x   x 
Cyclopropylfentanyl x x  x x x  x 
Despropionylfentanyl x x  x x   x 
Fentanyl x x x x x x x x 
Furanyl fentanyl x x x x x x x x 
Ocfentanyl x x x x x x x x 
ortho-Fluorofentanyl x x x x x   x 
Valerylfentanyl x x x x x x  x 
Other opioids AH-7921 x x x x x   x 
Codeine x x x x x x x x 
Dihydrocodeine x x x x x   x 
Hydrocodone x x x x x   x 
Isotonitazene  x  x    x 
Oxycodone x x x x x   x 
Tramadol x x x x x x x x 
U-47,700 x x x x x  x x 
Cathinones 3-MMC x x x x x x x x 
3,4-DMMC x x x x x   x 
4-Chloro-alpha-PVP x x x x x   x 
4-Chloroethcathinone x x x x x   x 
4-Chloromethcathinone x x x x x   x 
4-Cl-alpha-PPP  x x x    x 
4-Cl-Pentedrone  x  x    x 
4-Fluoro-alpha-PVP x x x x x   x 
4-MEC x x x x x x x x 
Alpha-PBP  x  x    x 
alpha-PEP (PV8) x x x x x   x 
alpha-PHP x x x x x   x 
alpha-PHPp x x x x x   x 
alpha-PVP x x x x x x x x 
Alpha-PVT  x x x    x 
bk-MDDMA x x x x x   x 
Buphedrone (MABP) x x x x x   x 
Butylone (bk-MDMB) x x x x x   x 
Dipentylone  x  x    x 
Ephylone (bk-EBDB)  x x x    x 
Ethylone (bk-MDEA) x x x x x   x 
F-alpha-PHP x x  x x   x 
MDPBP x x x x x   x 
MDPPP  x x x    x 
MDPV x x x x x x x x 
Mephedrone (4-MMC) x x x x x x x x 







(In bold: required minimum list of 







































Methedrone (bk-PMMA) x x x x x   x 
Methylone x x x x x x x x 
Mexedrone x x x x x   x 
N-acetyl mephedrone  x  x    x 
N-ethyl-pentedrone  x  x    x 
Naphyrone x x x x x   x 
N-ethylhexedrone x x x x x   x 
N-ethylnorpentedrone  x  x    x 
Pentedrone x x x x x x x x 
Synthetic 
cannabinoids 
4CN-Cumyl-BINACA  x  x    x 
5F-APINACA x x  x x x  x 
5F-MDMB-PINACA x x  x x   x 
5F-PB-22 x x  x x x  x 
AB-CHMINACA x x  x x   x 
AB-FUBINACA x x  x x   x 
AMB-FUBINACA x x  x x   x 
MMB-CHMINACA  x  x    x 
Benzodiazepines 3OH-Phenazepam x x x x x   x 
Alprazolam x x x x x x x x 
Bromazepam x x x x x   x 
Chlordiazepoxide x x x x x   x 
Clobazam x x x x x   x 
Clonazepam x x x x x x x x 
Clonazolam x x x x x   x 
Delorazepam x x x x x   x 
Deschloroetizolam x x x x x   x 
Desmethyldiazepam x x x x x x  x 
Diazepam x x x x x x x x 
Diclazepam x x x x x x  x 
Etizolam x x x x x x x x 
Flubromazepam x x x x x x  x 
Flubromazolam x x x x x x  x 
Flunitrazepam x x x x x x x x 
Lorazepam x x x x x   x 
Lormetazepam x x x x x   x 
Meclonazepam x x x x x   x 
Metizolam x x x x x   x 
Midazolam x x x x x x x x 
Nifoxipam x x x x x   x 
Nitrazepam x x x x x x  x 
Oxazepam x x x x x x x x 
Phenazepam x x x x x x  x 
Pyrazolam x x x x x   x 
Temazepam x x x x x  x x 
Piperidines 2-DPMP  x x x    x 
3,4-CTMP  x  x    x 
4-Fluoro-methylphenidate x x x x x   x 
Ethylphenidate x x x x x x x x 
Methylphenidate x x x x x x x x 
MDMA MDA x x x x x  x x 
MDEA x x x x x  x x 
MDMA x x x x x x x x 
Ketamine Ketamine x x x x x x x x 
Other medicines Bupropion x x x x x   x 
Carbamazepine x x x x x   x 
Doxepin  x x x    x 
Etorecoxib  x  x    x 
Gabapentin x x x x x   x 
Methiopropamine x x x x x x x x 
Methotrexate x x x x x  x x 
Piracetam  x x x    x 







(In bold: required minimum list of 







































Pregabalin x x x x x   x 
Propranolol  x x x    x 
Quetiapine x x x x x   x 
Sertraline  x x x    x 
Tiapride x x x x x   x 
Tizanidine x x x x x   x 
Zolpidem x x x x x x x x 
Zopiclone x x x x x x x x 
Other 
amphetamines 
3-Fluoromethamphetamine x x  x x   x 
4-Fluoro-amphetamine x x x x x  x x 
F-ethamphetamine  x  x    x 
N-acetylamphetamine  x  x    x 
N-propylamphetamine x x  x x   x 
PMA x x x x x   x 
PMMA x x  x x   x 
Other drugs 5-EAPB x x x x x  x x 
Amisulpride  x x x    x 
Mephtetramine x x x x x   x 




6-monoacetylmorphine (heroin) x x x x x x x x 
7-Aminoclonazepam (clonazepam) x x x x x x  x 
7-Aminoflunitrazepam (flunitrazepam) x x x x x x  x 
7-Aminonitrazepam (nitrazepam)  x x x  x  x 
10-monohydroxycarbamazepine 





α-hydroxy-alprazolam (alprazolam) x x x x x   x 
α-hydroxy-midazolam (midazolam) x x x x x   x 
Acetylcodeine (heroin)  x x x x x   x 
Amphetamine AC  x      x 
Benzoylecgonine (cocaine) x x x x x x x x 
Ecgonine methyl ester  x x    x x 
EDDP (methadone) x x x x x   x 
HMMA (MDMA) x x  x x   x 
Hydrocotarnine  x      x 
Meconin (opiate) x x x     x 
Metamizole breakdown  x x     x 
N-[2-(3,4-methylenedioxyphenyl)-1-





Nicotine  x x     x 
Norbuprenorphine (buprenorphine) x x x x x   x 
Norcocaine  x x     x 
Norcodeine  x x     x 
Normorphine  x x     x 
Noscapine  x x     x 
O-desmethyltramadol (tramadol) x x x x x   x 
Ritalinic acid  x x x    x 
Thebromine  x x     x 
Theophylline  x x     x 
Adulterants Caffeine x x x  x   x 
Dextromethorphan x x x x x x x x 
Dibutylhydroxytoluene  x      x 
Dimethylsulfone  x      x 
Diphenhydramine  x x x    x 
Griseofulvine x x x  x   x 
Hydroxyzine x x x x x   x 
Levamisole x x x x x x x x 
Lidocaine x x x  x   x 
Papaverin  x x     x 
Paracetamol x x x  x   x 
Phenacetin x x x  x   x 
 Procaine  x x     x 
ESCAPE Generic Protocol February 2021 
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Annex 4 Analytical methods used by laboratories (first two campaigns) 
 
Amsterdam/Lausanne Budapest Cologne Glasgow Oslo Paris
Unit of Forensic Toxicology and 
Chemistry, University Center of 
Legal Medicine, Lausanne-
Geneva
Toxicology Laboratory of the 
Institute of Forensic Medicine 
of the University of Debrecen
Institute of Forensic Medicine, 
Medical Centre, University of 
Freiburg
Forensic Medicine and Science 
(FMS), University of Glasgow
Departement of forensic 
Sciences, Oslo University 
Hospital
Laboratory of 
Public health and Environment 
Paris Sud University
I II
Method GC GC HPLC HPLC UHPLC UHPLC UHPLC UHPLC




DB-XLB capillary column 
(30 m length, 0.25 mm in 
diameter 
and 0.25 µm film thickness)
HP-35ms UI capillary column 
(30 m length, 0.25 mm in 
diameter 
and 0.25 µm film thickness)
Acclaim® RSLC 120 C18 
2.2 µm 120A 2.1x100 mm 
Phenomenex                      Gemini 
C18 (150 x 2mm, 5µm)
Waters Acquity CSH C18 75 mm, 
2.1 mm i.d., 1.7 µm particle + 5 
mm precolumn
Waters Acquity HSS T3 C18 150 
mm, 2.1 mm i.d., 1.7 µm particle 
+ 5 mm precolumn
Acquity HSS T3-column (2.1 x 
100 mm, 1.8 µm; Waters 
Corporation)
Waters Acquity UPLC BEH 
Phenyl 1.7 µm, 2.1x100 mm
Gas or Eluant Helium Helium
Eluent A: Water, 2 mM 
ammonium formate, 0.1% 
formic acid, 1% acetonitrile
Eluent B: Acetonitrile, 2 mM 
ammonium formate, 0.1% 
formic acid, 1% water
Eluant A: Deionised Water                  
Eluant B: Methanol                                    
A&B : supplemented to contain 
2mM Ammonium Acetate and 
0.1% Formic Acid
Eluent A: 5mM ammonium 
formate-0.05% formic acid
Eluent B: 100% acetonitrile
Eluent A: 5mM ammonium 
acetate-0.1% formic acid 
(aqueous); Eluent B: 100% 
methanol (organic), 
Eluent A: 5mM ammonium 
formate pH 3.1; Eluent B: 
Methanol.
Eluent A: 5mM formic acid 
/ammonium formate buffer








0.0 – 1.0 min: 1 % B
1.0 – 8.0 min: 1 % B to 95 % B
8.0 – 9.0 min: 95 % B
9.0 – 9.1 min: 95 % B to 1 % B
9.1 – 11.0 min: 1 % B
Flow Rate: 0.3 mL/min                         
Elution: Gradient and Isocractic
Gradient elution
0.5 ml/min flow
Gradient elution, 0.3 ml/min 
flow
flow rate : 0.4 mL/min
0.0 – 0.15 min: 5 % B
0.15 – 0.3 min: 30 % B
0.3 – 2.7 min: 50 % B
2.7 – 3.8 min: 90 % B 
3.8 – 4.6: 98 % B  
4.6 – 6.0: 5% B
flow rate : 0.4 mL/min
0.0 – 1.0 min: 2 % B
1.0 – 7.0 min: 98 % B
7.0 – 12.0 min: 98 % B
12.0 – 14.0 min: 2 % B 
14.0 – 15.1 min: 2 % B
Temperature
70 °C was held for 1 min, then 
increased to 200 °C (at 15 
°C/min) and to 300 °C (at 10 
°C/min). 300°C was held for 7 
min and then increased  to 320 
°C (30 °C/min), at which it was 
finally held for 3.67 min.
80 °C was held for 1 min, then 
increased to 300 °C (at 15 
°C/min) and the program was 
held for 21 min.
40 °C 40°C
6 °C (autosampler)
40 °C (UHPLC column)
10 °C (autosampler)
60 °C (UHPLC column)
65°C 40 °C
Runtime 31 min 37 min 11 min Variable 11.2 min + equilibration 18 min + equilibration 9 min 9 min + 6 min equilibration
I II
Method Mass detection Mass detection Mass detection Mass detection




Tandem mass spectrometry 
(MS/MS)
Tandem mass spectrometry 
(MS/MS)
Brand / model Agilent / 5973 Network Agilent / 5975C Bruker / amaZon speed AB Sciex / 3200 QTRAP Agilent / 6495 QqQ Bruker Daltonics MicroTOF Q II Agilent 6490 Triple Quadrupole
Thermo Scientific /
TSQ Quantum Access Max 
Temperature
230 °C for the ion source and 
150 °C for the quadrupole
230 °C for the ion source and 
150 °C for the quadrupole, EI 
mode
320 °C for the ESI ion source 
Ionisation: Turbo Ion Spray 
(Electrospray, ESI)                                          
held 350°C
350 °C (sheath gas) 200 °C (dry gas) Ion source at 300 °C Ion source at 300 °C
Scan mode Full Full Full Scan, MS², MS³ MRM
Dynamic multiple reaction 
monitoring (dMRM)
Full Scan MS and bbCID
Multiple reaction monitoring 
(MRM)
Multiple reaction monitoring 
(MRM)
Details
10–400 m/z mass range for the 
first 7 min then 30–550 m/z 
mass range, with a sampling 
rate of 2 scans/s
30–650 m/z mass range with a 
sampling rate of 2 scans/s
Scan range: 70 - 800 m/z
Scan speed: 32000 m/z*s-1
Data dependent acquisition of 
MS²and MS³ spectra
Spectral Library containing 
approx. 1050 compounds
MS  operated in QQQ mode not 
QTRAP mode
electrospray ionisation at 
positive mode (ESI+); 
multiwash and separate in-
house developed injection 
program for UHPLC separations
electrospray ionisation at 
positive mode (ESI+); 
automated compound ID and 
reporting based on a reverse 
search against an exact mass 
database with approx. 1200 
compounds
electrospray ionisation at 
positive mode (ESI+)






Forensic Toxicology Unit at National Institute for Health and 
Welfare
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